MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

Home・Akcijų sąrašas・Design Therapeutics Inc

Search

Design Therapeutics Inc

Uždarymo kaina

13.11

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

12.52

Max

13.39

Pagrindiniai rodikliai
By Trading Economics
Pajamos	1M -16M
Darbuotojai	54
EBITDA	-1.2M -18M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+18.14% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	179M 762M
Ankstesnė atidarymo kaina	13.11
Ankstesnė uždarymo kaina	13.11

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

3.26 / 3.63 Palaikymas ir pasipriešinimas

Design Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-20 23:49; UTC

Svarbiausios naujienos

New Zealand 1Q Inflation Higher Than Expected

2026-04-20 23:10; UTC

Karštos akcijos

Stocks to Watch: Amazon, Alaska Air Group, BridgeBio Oncology, AXT

2026-04-20 22:53; UTC

Pagrindinės rinkos jėgos

BridgeBio Oncology Shares Rise After FDA Fast-Tracks Pancreatic Cancer Treatment

2026-04-20 23:45; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

2026-04-20 23:44; UTC

Rinkos pokalbiai

Gold Consolidates as End of Cease-Fire Looms -- Market Talk

2026-04-20 23:39; UTC

Rinkos pokalbiai

Rio Tinto Posts Strong Start to Year -- Market Talk

2026-04-20 23:30; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-20 23:30; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-20 23:30; UTC

Rinkos pokalbiai

Super Retail's Earnings Outlook Less Rosy -- Market Talk

2026-04-20 23:09; UTC

Rinkos pokalbiai

Viva Energy's Refinery Fire More Benign Than Jefferies Thought -- Market Talk

2026-04-20 22:31; UTC

Įsigijimai, susijungimai, perėmimai

Anthropic, Amazon Tighten Bond in $5 Billion Investment and Computing Deal -- WSJ

2026-04-20 22:26; UTC

Įsigijimai, susijungimai, perėmimai

West African Resources Says Sanbrado, Toega Operations Not Subject to Govt Request for Additional Participation

2026-04-20 22:25; UTC

Įsigijimai, susijungimai, perėmimai

West African Resources Plans to Distribute Cash Proceeds to Shareholders Via Special Dividend

2026-04-20 22:25; UTC

Įsigijimai, susijungimai, perėmimai

West African Resources Aims for Acquisition to Be Completed by End-2026

2026-04-20 22:25; UTC

Įsigijimai, susijungimai, perėmimai

West African Resources Says to Work Cooperatively With Govt to Finalize Deal Terms

2026-04-20 22:25; UTC

Įsigijimai, susijungimai, perėmimai

West African Resources Says Acquisition Would Be for A$175 Million

2026-04-20 22:24; UTC

Įsigijimai, susijungimai, perėmimai

West African Resources Says Burkina Faso Govt Issues Decree to Acquire 25% of Kiaka

2026-04-20 22:15; UTC

Įsigijimai, susijungimai, perėmimai

Anthropic, Amazon Tighten Bond in $5 Billion Investment and Computing Deal -- WSJ

2026-04-20 22:01; UTC

Įsigijimai, susijungimai, perėmimai

Amazon Invests $5B in Anthropic Amid Expanded Collaboration

2026-04-20 21:38; UTC

Rinkos pokalbiai

Apple's New CEO Will Face Immediate Pressure on AI Strategy -- Market Talk

2026-04-20 21:33; UTC

Įsigijimai, susijungimai, perėmimai

Uber Expands Stake In Lucid for Robo-Taxis. This Is How Tesla's Stock Is Responding. -- Barrons.com

2026-04-20 21:24; UTC

Rinkos pokalbiai

Apple's CEO Change Timing Will Garner Mixed Reaction, Analyst Says -- Market Talk

2026-04-20 21:24; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-20 21:13; UTC

Uždarbis

Alaska Air: Expansion of Card Portfolio Expected to Accelerate Loyalty Platform Beyond Incremental $150M Profit Outlined in Alaska Accelerate Strategy

2026-04-20 21:10; UTC

Uždarbis

Alaska Air to Move Toward a Single Issuer for Atmos Rewards Credit Cards

2026-04-20 21:09; UTC

Uždarbis

Alaska Air Sees 2Q Capacity Up About 1% Year-Over-Year, Down Nearly a Point From Original Views, on 'Proactive Trimming' of May and June Capacity

2026-04-20 21:08; UTC

Uždarbis

Alaska Air 'Continues to Operate From a Position of Strength,' With Healthy Balance Sheet, Strong Liquidity, About $20B in Unencumbered Assets

2026-04-20 21:07; UTC

Uždarbis

Alaska Air: Taken Together, Rev, Cost and Fuel Assumptions Result in 2Q Adjusted Loss Per Share Estimate of About $1

2026-04-20 21:05; UTC

Uždarbis

Alaska Air: This Assumption Adds About $600M of Expense to 2Q, Equivalent to EPS Headwind of $3.60

2026-04-20 21:05; UTC

Uždarbis

Alaska Air Expects 2Q Fuel Cost to Average About $4.50 Based on Forward Curve Today

Akcijų palyginimas

Kainos pokytis

Design Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

18.14% į viršų

12 mėnesių prognozė

Vidutinis 15.5 USD 18.14%

Aukščiausias 18 USD

Žemiausias 14 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Design Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

4

Pirkti

0

Laikyti

0

Parduoti

Remiantis 4 analitikų, pateikusių Design Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

3.26 / 3.63Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Kitos sektoriaus akcijos

MDT

Medtronic PLC

85.26

A

Agilent Technologies Inc

120.85

VEEV

Veeva Systems Inc

168.97

HQY

HealthEquity Inc

86.11

NEOG

Neogen Corp

9.63

Live chat